Himmelreich Jeffrey C 4

What Happened
Jeffrey C. Himmelreich, Head of Finance at MAIA Biotechnology, was granted 60,000 derivative instruments (stock options) on May 29, 2026. The Form 4 reports an acquisition price of $0.00, which reflects that this was an option award (not a cash purchase of common stock) rather than a market trade. No cash value or exercise price is stated in the summary provided.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-01 (filed within the required two business days).
• Grant: 60,000 stock options reported as a derivative acquisition with $0.00 shown on the Form 4.
• Vesting: Options vest over 4 years — 25% vest on the first anniversary of the grant, then the remainder vests ratably each month over the next 36 months (per footnote).
• Shares owned after transaction: Not specified in the information provided; consult the full Form 4 filing for beneficial ownership totals.
• Not an exercise or sale: This is a grant/award of options (transaction code A), not an exercise (M) or sale (S).

Context
Option grants are a common form of executive compensation intended to align management with shareholder interests; they do not represent immediate market purchases or sales unless exercised and sold later. Because this was an award, it should be interpreted as a compensation event rather than a direct bullish or bearish trade signal. Check future filings for exercises, sales, or changes in beneficial ownership.